High prevalence of diabetes mellitus and impaired glucose tolerance in liver cancer patients: A hospital based study of 4610 patients with benign tumors or specific cancers

Roujun, Chen; Yi, Yanhua; Li, Bi-Xun

doi:10.12688/f1000research.8457.1

Cited by 4 publications

(3 citation statements)

References 23 publications

(19 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Meta-analysis of three studies conducted in Asia also showed an inverse association between DM and NPC (OR =0.62, 95% CI: 0.39–0.97, P =0.04) ( Figure 2 ). 15 – 17 The above results suggest that DM appears to be correlated with a trend toward decreased NPC risk, which is quite different from the finding that DM is positively associated with an increased risk of most other cancers.…”

Section: Resultscontrasting

confidence: 80%

See 1 more Smart Citation

Impact of diabetes mellitus on the risk and survival of nasopharyngeal carcinoma: a meta-analysis

Guo¹,

Fu²,

Wei³

et al. 2018

OTT

View full text Add to dashboard Cite

BackgroundDiabetes mellitus (DM) has been identified to be both a risk factor and a prognostic factor in a variety of malignancies, but its association with the risk and outcome of nasopharyngeal carcinoma (NPC) is still unclear. To elucidate this issue, we systematically reviewed the evidence concerning the association between DM status and NPC.Materials and methodsWe identified studies by a literature search of PubMed, Embase, and ISI Web of Knowledge through May 31, 2017, and by searching the reference lists of pertinent articles. Odds ratios (ORs) and hazard ratios (HRs) with 95% CIs were used to estimate the effect size. Heterogeneity across studies was evaluated by the Cochran’s Q and I2 statistics.ResultsA total of nine studies were included. Four studies with a total sample size of 221,611 reported the effect of DM on NPC risk, and the other five studies with a sample size of 9,442 reported the impact of DM on survival in NPC patients. All included studies were retrospective, and mostly conducted in Asian populations. Meanwhile, condition of metformin usage was not considered in all studies. A pooled OR of 0.65 (95% CI: 0.43–0.98, P=0.04) revealed an inverse association between DM and NPC. Additionally, pooled analyses of studies investigating the prognosis value of DM revealed that preexisting DM had no effect on overall survival (HR =1.17, 95% CI: 0.94–1.46, P=0.16), local recurrence-free survival (HR =1.16, 95% CI: 0.80–1.67, P=0.44), and distant metastasis-free survival (HR =1.14, 95% CI: 0.92–1.40, P=0.22).ConclusionOur results suggested that DM patients might have decreased NPC risk, and have little impact on prognosis of NPC patients. This conclusion should be limited to Asian population. Our results also suggest that more attention should be paid to metformin medication in further studies in order to clarify whether the effects of DM on NPC risk and prognosis are influenced by the anticancer effect of metformin.

show abstract

Section: Resultscontrasting

confidence: 80%

“…The lack of comparability between groups was found in two studies. 15 , 17 The study of Tseng et al did not exclude potential cancer patients in the control group at the initial time of identifying patients. 16 …”

Section: Resultsmentioning

confidence: 99%

Impact of diabetes mellitus on the risk and survival of nasopharyngeal carcinoma: a meta-analysis

Guo¹,

Fu²,

Wei³

et al. 2018

OTT

View full text Add to dashboard Cite

show abstract

“…Findings of previous studies have pointed in the same direction. 21,27,31,32 In contrast to earlier studies, our results provide a systematic overview of the prevalence of preDM and DM for various cancer types. 33 For most of these cancer types, the prevalence of preDM has never been reported.…”

Section: Original Research Cancer and Diabetesmentioning

confidence: 72%

Understanding the Prevalence of Prediabetes and Diabetes in Patients With Cancer in Clinical Practice: A Real-World Cohort Study

Ose

Viskochil

Holowatyj

et al. 2021

Journal of the National Comprehensive Cancer Network

View full text Add to dashboard Cite

Background: This study aimed to understand the prevalence of prediabetes (preDM) and diabetes mellitus (DM) in patients with cancer overall and by tumor site, cancer treatment, and time point in the cancer continuum. Methods: This cohort study was conducted at Huntsman Cancer Institute at the University of Utah. Patients with a first primary invasive cancer enrolled in the Total Cancer Care protocol between July 2016 and July 2018 were eligible. Prevalence of preDM and DM was based on ICD code, laboratory tests for hemoglobin A1c, fasting plasma glucose, nonfasting blood glucose, or insulin prescription. Results: The final cohort comprised 3,512 patients with cancer, with a mean age of 57.8 years at cancer diagnosis. Of all patients, 49.1% (n=1,724) were female. At cancer diagnosis, the prevalence of preDM and DM was 6.0% (95% CI, 5.3%–6.8%) and 12.2% (95% CI, 11.2%–13.3%), respectively. One year after diagnosis the prevalence was 16.6% (95% CI, 15.4%–17.9%) and 25.0% (95% CI, 23.6%–26.4%), respectively. At the end of the observation period, the prevalence of preDM and DM was 21.2% (95% CI, 19.9%–22.6%) and 32.6% (95% CI, 31.1%–34.2%), respectively. Patients with myeloma (39.2%; 95% CI, 32.6%–46.2%) had the highest prevalence of preDM, and those with pancreatic cancer had the highest prevalence of DM (65.1%; 95% CI, 57.0%–72.3%). Patients who underwent chemotherapy, radiotherapy, or immunotherapy had a higher prevalence of preDM and DM compared with those who did not undergo these therapies. Conclusions: Every second patient with cancer experiences preDM or DM. It is essential to foster interprofessional collaboration and to develop evidence-based practice guidelines. A better understanding of the impact of cancer treatment on the development of preDM and DM remains critical.

show abstract

Mean platelet volume predicts survival in patients with hepatocellular carcinoma and type 2 diabetes

Yin

Niu

Qian³

et al. 2019

Diabetes Research and Clinical Practice

View full text Add to dashboard Cite

High prevalence of diabetes mellitus and impaired glucose tolerance in liver cancer patients: A hospital based study of 4610 patients with benign tumors or specific cancers

Cited by 4 publications

References 23 publications

Impact of diabetes mellitus on the risk and survival of nasopharyngeal carcinoma: a meta-analysis

Impact of diabetes mellitus on the risk and survival of nasopharyngeal carcinoma: a meta-analysis

Understanding the Prevalence of Prediabetes and Diabetes in Patients With Cancer in Clinical Practice: A Real-World Cohort Study

Mean platelet volume predicts survival in patients with hepatocellular carcinoma and type 2 diabetes

Contact Info

Product

Resources

About